Video

Dr. Edington on the Evolving Treatment Paradigm of Melanoma

Howard D. Edington, MD, discusses the evolving treatment paradigm of melanoma.

Howard D. Edington, MD, director, Cutaneous Oncology Program, Melanoma and Skin Cancer Center, Allegheny Health Network, discusses the evolving treatment paradigm of melanoma.

Medical therapy has undergone tremendous advances in melanoma in recent years, Edington says. The prognosis for stage IV disease, or advanced melanoma, used to be dismal, and now it has become manageable, Edington says.

Despite the progress in treating melanoma, areas of need remain, and the incidence of disease has continued to increase, Edington explains. Recent data suggest that by the year 2040, melanoma will be the second-most commonly diagnosed cancer, trailing only breast cancer, Edington concludes.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center